EU/3/11/872: Orphan designation for the treatment of hepatocellular carcinoma

Sulfonated monophosphorylated mannose oligosaccharide


On 21 June 2011, orphan designation (EU/3/11/872) was granted by the European Commission to S-cubed Limited, United Kingdom, for sulfonated monophosphorylated mannose oligosaccharide for the treatment of hepatocellular carcinoma.

Key facts

Active substance
Sulfonated monophosphorylated mannose oligosaccharide
Intended use
Treatment of hepatocellular carcinoma
Orphan designation status
EU designation number
Date of designation

S-Cubed Pharmaceutical Services ApS
Baneledet 2
3600 Frederikssund

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

January 2019The sponsorship was transferred to S-cubed Pharmaceutical Services ApS, Denmark, in January 2019.
June 2023The sponsor’s address was updated in June 2023.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating